Drugs / Iscador*P
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04376931 | Dec 2020 → Jul 2022 | — | HaEmek Medical Center, Israel | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05726383 | May 2024 → May 2027 expected | osteosarcoma | Hackensack Meridian Health | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Iscador*P | “Iscador®P: fermented aqueous extract of mistletoe grown on pine tree (Viscum album L. subspecies austriacum (Wiesb.) Vollmann)” NCT04376931 ↗2“Iscador® P is to be injected subcutaneously (abdominal) 3 times/week.” NCT05726383 ↗ “Drug: Iscador*P” NCT05726383 ↗ |
| Route | Intravenous | “Iscador®P as intravenous infusion” NCT04376931 ↗ |